Brokerages Set Health Catalyst, Inc. (NASDAQ:HCAT) PT at $2.77

Health Catalyst, Inc. (NASDAQ:HCAT) has earned a consensus rating of “Hold” from the thirteen analysts that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $2.8409.

A number of equities analysts have commented on the stock. Stifel Nicolaus reduced their price target on shares of Health Catalyst from $3.75 to $2.00 and set a “hold” rating on the stock in a research report on Friday, March 13th. Raymond James Financial set a $3.00 target price on shares of Health Catalyst in a research note on Friday, March 13th. Canaccord Genuity Group dropped their target price on shares of Health Catalyst from $5.00 to $2.00 and set a “buy” rating for the company in a research note on Friday, March 13th. Citigroup dropped their target price on shares of Health Catalyst from $2.75 to $1.75 and set a “neutral” rating for the company in a research note on Friday, March 13th. Finally, Stephens dropped their target price on shares of Health Catalyst from $2.00 to $1.75 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th.

Health Catalyst Price Performance

NASDAQ:HCAT opened at $1.90 on Tuesday. The firm has a market cap of $140.39 million, a PE ratio of -0.51 and a beta of 1.66. Health Catalyst has a 12 month low of $0.96 and a 12 month high of $4.13. The company has a quick ratio of 1.69, a current ratio of 1.69 and a debt-to-equity ratio of 1.10. The company’s 50-day moving average price is $1.49 and its two-hundred day moving average price is $1.76.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Monday, May 11th. The company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.01. The firm had revenue of $70.76 million for the quarter, compared to analyst estimates of $69.24 million. Health Catalyst had a negative net margin of 87.69% and a negative return on equity of 3.52%. On average, equities analysts anticipate that Health Catalyst will post -0.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Health Catalyst

A number of institutional investors have recently modified their holdings of HCAT. nVerses Capital LLC bought a new position in shares of Health Catalyst in the fourth quarter worth about $25,000. Cresset Asset Management LLC bought a new position in shares of Health Catalyst in the second quarter worth about $39,000. FNY Investment Advisers LLC bought a new position in shares of Health Catalyst in the third quarter worth about $45,000. Focus Partners Wealth bought a new stake in shares of Health Catalyst during the first quarter worth approximately $46,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Health Catalyst by 71.7% during the third quarter. BNP Paribas Financial Markets now owns 16,355 shares of the company’s stock worth $47,000 after buying an additional 6,832 shares during the last quarter. 85.00% of the stock is owned by institutional investors.

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.